

Name of the Cell line	Type of cell line	IC Values (nM)		
		GDC-0941	Compound 1	Compound 2
NCI-H292	Lung cancer	638 (Lit: 750)	836	643
HCC827	Lung cancer	1397 (Lit:1200)	1708	1495
A549	Lung cancer	8776 (Lit: 6800)	3491	2009
MDA-MB-361	Breast cancer	114 (Lit: 140)	364	151
MDAMB-231	Breast cancer	>10000(Lit: >10000)	4033	9793
MIAPaCa-2	Pancreatic cancer	1766	1128	1064
PC3	Prostate cancer	1048	1439	1060
U-87	Glioma	>10000	5349	10000

Figure-1: Anti-proliferative activity of compound-1 & 2 on various solid tumor cell lines

S. No.	Group	No. of animals	Initial tumor volume (Mean $\pm$ SEM)	Tumor volume after treatment (Mean $\pm$ SEM)			
				3 rd Day	7 th Day	15 th Day	23 rd Day
I	Control (Vehicle) (2% Gum acacia + 2% SLS)	5	273.84 $\pm$ 77.35	325.04 $\pm$ 63.56	507.48 $\pm$ 61.10	1020.8 $\pm$ 190.96	2098.8 $\pm$ 174.34
II	Compound 2 (200 mg/kg, p.o)	5	398.39 $\pm$ 53.20	355.95 $\pm$ 43.13	240.90 $\pm$ 22.83	116.41 $\pm$ 21.98	35.13 $\pm$ 2.07***
III	Compound 1 (50 mg/kg, p.o)	5	421.27 $\pm$ 113.24	387.16 $\pm$ 102.90	280.22 $\pm$ 76.03	130.82 $\pm$ 55.19	40.13 $\pm$ 31.89***
IV	Standard [Erlotinib (50 mg/kg, p.o) + Gemcitabine (120 mg/kg, i.p)]	5	342.47 $\pm$ 64.06	322.57 $\pm$ 49.75	194.58 $\pm$ 27.56	86.28 $\pm$ 18.23	20.72 $\pm$ 8.91***

Figure 2: Anti-tumor activity of COMPOUND 1 and COMPOUND 2 against tumor induced by pancreatic cell Line MIAPaca-2 in nude mice




Figure 3: Anti-tumor activity of COMPOUND 1 against tumor induced by NCI-H292 (Lung cancer/ Erlotinib resistant)




Figure 4: Anti-tumor activity of COMPOUND 2 against tumor induced by NCI-H292 (Lung cancer/Erlotinib resistant)